Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin - Heart Failure Reviews
Source : https://link.springer.com/article/10.1007/s10741-022-10228-8
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent syndrome with multifaceted pathophysiology. All approaches to neurohormonal modulation were shown not to improve survival in HFpEF, despite their...
Relevance: This paper recapitulates the journey from the failure of trials on neurohormonal antagonists to the attempts of personalized approaches and the new perspectives of SGLT2i therapy for HFpEF.
Share
Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.869272/full
BackgroundThe efficacy of dapagliflozin and empagliflozin in sodium-glucose cotransport-2 inhibitors (SGLT-2i) in patients with heart failure (HF) has been discovered. However, which drug could improve varied prognostic outcomes has not...
Recommendations: Overall, 10 mg/day dapagliflozin may be the optimal recommendation for its premium and comprehensive effect on improving the prognosis of patients with HF compared to 10 mg/day empagliflozin.
Share
In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance) | The Medical Letter, Inc.
Source : https://secure.medicalletter.org/w1648a
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance - Boehringer Ingelheim) was approved by the FDA in 2021 to reduce the risk of hospitalization for heart failure (HF) and...
CONCLUSION: Addition of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) to standard treatment for heart failure with preserved ejection fraction reduced the composite risk of hospitalization for heart failure or cardiovascular death in patients with an LVEF >40%, with or without type 2 diabetes....
Share
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35450095/
1 Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. 2 Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 3 Assistant Professor...
Conclusion: In this review, we will discuss the known mechanisms SGLT2i exploit to provide their beneficial effects, the potential benefits, and risks of these agents in the context of kidney transplantation, and finally, we will discuss current findings of the published literature for SGLT2i use in kidney transplant recipients and propose...
Share
Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35443373/
Overall, FDC of Remogliflozin Etabonate + Vildagliptin added on to Metformin was found to be efficacious and well tolerated in the treatment of patients with T2DM, and demonstrated non-inferiority to...
Conclusion: Overall, FDC of Remogliflozin Etabonate Vildagliptin added on to Metformin was found to be efficacious and well tolerated in the treatment of patients with T2DM, and demonstrated non-inferiority to Empagliflozin 25mg Linagliptin 5mg treatment added on to Metformin.
Share